Moreover, since many of the recruited high risk patients tested negative for BRCA1/2 mutations, it is plausible to take advantage of the collected DNA samples and test for mutations in other breast cancer susceptibility genes, e.g. CHEK2, PALB2 and BRIP1. Here, PALB2 is linked to breast cancer.